# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

> **NCT04650126** · PHASE1 · COMPLETED · sponsor: **Baliopharm Pty Ltd** · enrollment: 42 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** ATM001
- **BIOLOGICAL:** ATM001 Placebo

## Key facts

- **NCT ID:** NCT04650126
- **Lead sponsor:** Baliopharm Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-12
- **Primary completion:** 2022-03-24
- **Final completion:** 2022-03-24
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04650126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04650126, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04650126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*